Last updated: February 25, 2026
What Is the Clinical and Market Profile of Erenumab?
NDC 70677-1094 refers to a specific formulation of erenumab, marketed as Aimovig. Erenumab is a calcitonin gene-related peptide (CGRP) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) in 2018 for preventive treatment of migraine in adults.
The drug's primary indication targets chronic and episodic migraines with significant impact on patients' quality of life. The pharmacological profile includes a fixed dose of 70 mg or 140 mg administered monthly via subcutaneous injection.
How Has the Market for Erenumab Developed?
Market Size and Growth
The migraine therapeutics market has grown steadily since 2018, driven by the unmet need for effective preventive treatments. Estimates from analysts project a compound annual growth rate (CAGR) around 8-10% from 2023 to 2028.
Competitive Landscape
Erenumab's main competitors are other CGRP inhibitors, including:
- Fremanezumab (Ajovy)
- Galcanezumab (Emgality)
- Eptinezumab (Vyepti)
Additional classes include monoclonal antibodies and small-molecule NSAIDs. Erenumab maintains a market share estimated at 40-45% within CGRP class due to early approval and clinician familiarity.
Market Penetration and Reimbursement Dynamics
High cost remains a barrier, with list prices around $6,900 per year for 70 mg and $13,800 for 140 mg doses. Insurance coverage varies, with payers increasingly requiring prior authorization and step therapy protocols.
What Are Price Projections Based on Current Trends?
Historical Pricing Data
- Launch price (2018): approximately $6,900 annually (for 70 mg dose)
- 2020: price stabilized; rebate discounts and insurer negotiations impacted net prices
- 2022: list price held steady; some discounts offered to improve formulary access
Future Price Trends (2023-2028)
Factors influencing pricing include:
- Competitive entry by biosimilars or newer agents
- Payer negotiation strategies
- Policy shifts toward value-based pricing
Price projections indicate a potential price decrease of 10-15% over five years, influenced by increased biosimilar competition and pressure to reduce healthcare costs. List prices might decline to approximately $6,000-6,500 annually for the 70 mg dose by 2028.
Impact of Biosimilar Entry and Market Saturation
No biosimilars of erenumab have entered the market as of 2023. However, regulatory pathways are evolving, and late-stage development of biosimilar candidates may influence future pricing.
Revenue Forecasts
Projected global annual sales could reach $4 billion by 2028, assuming continued growth and market penetration in North America, Europe, and select Asia-Pacific markets.
Risks and Opportunities
Risks
- Entry of biosimilars or generics may reduce prices
- Payer restrictions could limit access
- Label expansions or new indications could shift pricing dynamics
Opportunities
- Expansion into new indications such as cluster headaches
- Increased use in early intervention strategies
- Value-based contracts linking reimbursement to patient outcomes
Key Market Data Summary
| Parameter |
2023 Estimate |
2028 Projection |
| Market size (USD) |
$1.2 billion |
$4.0 billion |
| Annual price per patient (USD) |
$6,900 (70 mg dose) |
$6,000-$6,500 |
| Market penetration |
35-45% of diagnosed patients |
60-70% of eligible patients |
| CAGR |
8-10% |
8-10% |
Conclusion
Erenumab's pricing is likely to experience slight downward pressure over the next five years due to market saturation, competitive dynamics, and reimbursement policies. Its revenue growth depends on broader adoption in migraine populations and potential expansion into new indications.
Key Takeaways
- The U.S. migraine prophylaxis market is expanding at 8-10% CAGR, with erenumab holding a leading position.
- List prices remain stable but are expected to decline by 10-15% within five years.
- No biosimilar competition exists as of 2023, but future entry could significantly affect pricing.
- Market growth depends on increased uptake, payer coverage, and new potential indications.
FAQs
-
When was erenumab approved, and what is its primary use?
Erenumab was approved in 2018 for preventing episodic and chronic migraines in adults.
-
What is the current list price of erenumab in the U.S.?
Approximately $6,900 annually for the 70 mg dose; $13,800 for 140 mg.
-
How might biosimilar competition impact erenumab's pricing?
Biosimilar entry could drive list prices down by 20-30%, depending on market acceptance and payer negotiations.
-
What therapeutic alternatives exist besides erenumab?
Other CGRP inhibitors like fremanezumab, galcanezumab, and eptinezumab, and traditional prophylactic drugs.
-
What are the key factors influencing erenumab's revenue forecast?
Market penetration, pricing trends, insurance coverage, and competition from biosimilars or new therapies.
References
- U.S. Food and Drug Administration. (2018). FDA approves first medication for chronic migraines. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-chronic-migraines
- IQVIA. (2022). Global Prescription Drug Market Data.
- Evaluate Pharma. (2023). Migraine Treatment Market Outlook.
- CMS. (2023). Medicare and Medicaid Reimbursement Policies.
- Pharmaceutical Research and Manufacturers of America. (2022). Biosimilar Development and Entry Timeline.
